34626-05-6

Basic information

• Product Name: 2-(4-chlorophenyl)-4-carboxy-1H-imidazole
• Synonyms: 2-(4-chlorophenyl)-4-carboxy-1H-imidazole
• CAS NO: 34626-05-6
• Molecular Weight: 222.631
• Mol File: 34626-05-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-(4-chlorophenyl)-4-carboxy-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-chlorophenyl)-4-carboxy-1H-imidazole(34626-05-6)
• EPA Substance Registry System: 2-(4-chlorophenyl)-4-carboxy-1H-imidazole(34626-05-6)

Safety Data

• Hazardous Substances Data: 34626-05-6(Hazardous Substances Data)

Usage

General Description

2-(4-chlorophenyl)-4-carboxy-1H-imidazole, also known as clotrimazole, is an antifungal medication commonly used to treat various fungal infections, including athlete's foot, ringworm, and yeast infections. It works by inhibiting the growth of fungi and disrupting their cell membranes. Clotrimazole is classified as an imidazole antifungal agent and is available in various forms such as creams, lotions, and oral lozenges. It is generally considered safe for topical use with minimal side effects, although allergic reactions and skin irritation may occur in some individuals. Clotrimazole is widely available over the counter and is a commonly used treatment for fungal infections.

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 33469-15-7 2-(4-chlorophenyl)-4-trifluoromethyl-1H-imidazole 
• 33469-15-7 2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-imidazole 

Downstream Products

• 279251-15-9 2-(4-chlorophenyl)-1H-imidazole-4-carbaldehyde 
• 279250-69-0 2-(4-chlorophenyl)-4-(N-methyl-N-methoxyaminocarbonyl)-1H-imidazole 

Relevant articles and documents

Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD)

A series of 2-Aryl-4-Bis-amide Imidazoles (ABAI-1 to 30) were designed as anti-inflammatory agents. These compounds were synthesized and evaluated for the in vitro anti-inflammatory activities (inhibition of NO production and release of inflammatory cytok

Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120

In our attempt to optimize the lead HIV-1 entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogues and determination of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure-activity relationship (SAR). Two of these compounds, NBD-14088 and NBD-14107, showed significant improvement in antiviral activity compared to the lead entry antagonist in a single-cycle assay against a large panel of Env-pseudotyped viruses. The X-ray structure of a similar compound, NBD-14010, confirmed the binding mode of the newly designed compounds. The in vitro ADMET profiles of these compounds are comparable to that of the most potent attachment inhibitor BMS-626529, a prodrug of which is currently undergoing phase III clinical trials. The systematic study presented here is expected to pave the way for improving the potency, toxicity, and ADMET profile of this series of compounds with the potential to be moved to the early preclinical development.

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.